You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogAlready a…
10th of August Zealand Pharma became the first Danish biotech company to be listed on Nasdaq in Denmark as well as the US. With the dual listing, Zealand Pharma will become more attractive to US investors. ”To us it is an achievement and a major milestone that we today show…
TheUS Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraAlready a subscriber Login You have…
Recipharm has announced that it will initiate a process with the intention of discontinuing manufacturing operations at its facilities in Stockholm and Höganäs, Sweden. Since 2015, Recipharm has been implementing efficiency activities in the Swedish part of the business segment known as Solids Already a subscriber Login You have read…
